PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of pharmscispringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSci. Mar 2004; 6(1): 86–93.
Published online Mar 9, 2004. doi:  10.1208/ps060109
PMCID: PMC2750944
Pharmacokinetic model of target-mediated disposition of thrombopoietin
Feng Jin and Wojciech Krzyzanskicorresponding author
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, 565B Hochstetter Hall, 14260 Buffalo, NY
Wojciech Krzyzanski, Phone: (716)645-2942, Fax: (716)645-3693, wk/at/buffalo.edu.
corresponding authorCorresponding author.
Received August 21, 2003; Accepted February 1, 2004.
Thrombopoietin, TPO, a 353 amino acid cytokine, is a primary regulator of platelet production that was cloned recently. A target-mediated (platelet receptors) pharmacokinetic model was developed to characterize the disposition of TPO. Receptor-mediated endocytosis was assigned as the major elimination pathway in the model. A nonspecific binding compartment was also incorporated into the model. TPO concentration vs time profiles from a published phase 1 and 2 clinical trial were used to apply this model. Noncompartmental analysis demonstrated that TPO exhibits nonlinear kinetics. The proposed model captured the concentration-time profiles relatively well. The first-order internalization rate constant was estimated as 0.1 h−1. The endogenous binding capacity was estimated as 164.0 pM. The second-order binding association constant (kon) was 0.055 h−1·pM−1 and the first-order dissociation constant (koff) was estimated as 2.5 h−1, rendering the equilibrium dissociation constant Kd as 45.5 pM. This model may be relevant to other therapeutic agents with receptor-mediated endocytotic disposition.
Keywords: thrombopoietin, receptor-mediated drug disposition, pharmacodynamic model
1. Bartley TD, Bogenberger J, Hunt P, Li YS, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor. Mpl. Cell. 1994;77:1117–1124. doi: 10.1016/0092-8674(94)90450-2. [PubMed] [Cross Ref]
2. Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533–538. doi: 10.1038/369533a0. [PubMed] [Cross Ref]
3. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994;91:11104–11108. doi: 10.1073/pnas.91.23.11104. [PubMed] [Cross Ref]
4. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine TPO cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565–568. doi: 10.1038/369565a0. [PubMed] [Cross Ref]
5. Sohma Y, Akahori H, Seki N, et al. Molecular cloning and chromosomal localization of the human TPO gene. FEBS Lett. 1994;353:57–61. doi: 10.1016/0014-5793(94)01008-0. [PubMed] [Cross Ref]
6. Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A. 1992;89:5640–5644. doi: 10.1073/pnas.89.12.5640. [PubMed] [Cross Ref]
7. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood. 1995;85:391–401. [PubMed]
8. Kaushansky K, Broudy VC, Lin N, et al. TPO, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A. 1995;92:3234–3238. doi: 10.1073/pnas.92.8.3234. [PubMed] [Cross Ref]
9. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Recombinant human TPO (Mpl ligand) enhances proliferation of erythroid progenitors. Blood. 1995;86:2494–2499. [PubMed]
10. Simicka E, Lin N, Priestley GV, et al. The effect of TPO on the proliferation and differentiation of murine hematopoietic stem cells. Blood. 1996;87:4998–5005. [PubMed]
11. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand TPO. Nature. 1994;369:568–571. doi: 10.1038/369568a0. [PubMed] [Cross Ref]
12. Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood. 1995;86:4486–4492. [PubMed]
13. Cardier JE, Dempsey J. TPO and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: evidence of TPO as a growth factor for liver endothelial cells. Blood. 1998;91:923–929. [PubMed]
14. Sungaran R, Markovic B, Chong BH. Localization and regulation of TPO mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood. 1997;89:101–107. [PubMed]
15. Kuter DJ, Rosenberg RD. The reciprocal relationship of TPO (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 1995;85:2720–2730. [PubMed]
16. Bondurant MC, Koury MJ. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol. 1986;6:2731–2733. [PMC free article] [PubMed]
17. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of TPO levels by c-mpl-mediated binding to platelets. Blood. 1996;87:2154–2161. [PubMed]
18. Sugiyama Y, Hanano M. Receptor-mediated transport of peptide hormones and its importance in the overall homone disposition in the body. Pharm Res. 1989;6:192–202. doi: 10.1023/A:1015905331391. [PubMed] [Cross Ref]
19. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507–532. doi: 10.1023/A:1014414520282. [PubMed] [Cross Ref]
20. Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of TPO. Blood. 1997;89:2782–2788. [PubMed]
21. Li J, Xia Y, Kuter DJ. Interaction of TPO with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106:345–356. doi: 10.1046/j.1365-2141.1999.01571.x. [PubMed] [Cross Ref]
22. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for TPO. Blood. 1997;89:1896–1904. [PubMed]
23. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human TPO in patients with cancer. Ann Intern Med. 1997;126:673–681. [PubMed]
24. D Argenio DZ, Schumitzky A. ADAPT II Users Guide. Los Angeles, CA: Biomedical Simulations Resource; 1997.
25. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56:248–252. [PubMed]
26. Kuter DJ. TPOs and thrombopoiesis: a clinical perspective. Vox Sang. 1998;74:75–85. [PubMed]
27. Braeckman R. Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Reid RE, editor. Peptide and Protein Drug Analysis. New York, NY: Marcel Dekker; 2000. pp. 633–669.
28. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21:457–478. doi: 10.1007/BF01061691. [PubMed] [Cross Ref]
29. Krzyzanski W, Ramakrishnan R, Jusko WJ. Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm. 1999;27:467–489. [PubMed]
30. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationship to cytokine serum levels and prognostic significance. Ann Oncol. 2001;12:1423–1432. doi: 10.1023/A:1012527006566. [PubMed] [Cross Ref]
31. Emmons RV, Reid DM, Cohen RL, et al. Human TPO levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068–4071. [PubMed]
32. Rowland M, Tozer TN, Rowland R. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia, PA: Lippincott, Williams & Wilkins; 1995.
33. Cheng HY, Jusko WJ. Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis-Menten equation. Pharm Res. 1988;5:156–164. doi: 10.1023/A:1015960806202. [PubMed] [Cross Ref]
34. Jusko WJ. Pharmacokinetics of capacity-limited systems. J Clin Pharmacol. 1989;29:488–493. [PubMed]
35. Lin JH. Dose-dependent pharmacokinetics: experimental observations and theoretical considerations. Biopharm Drug Dispos. 1994;15:1–31. doi: 10.1002/bdd.2510150102. [PubMed] [Cross Ref]
Articles from AAPS PharmSci are provided here courtesy of
American Association of Pharmaceutical Scientists